Current Hypertension Reports

, Volume 7, Issue 5, pp 348–354

Hypertension in pregnancy

  • Maryann Mugo
  • Gurushankar Govindarajan
  • L. Romayne Kurukulasuriya
  • James R. Sowers
  • Samy I. McFarlane


Hypertension in pregnancy contributes significantly to both maternal and neonatal morbidity and mortality. Among different forms of pregnancy-associated hypertension, preeclampsia-eclampsia has the highest impact on morbidity and mortality. Chronic hypertension may result in preterm and small for gestational age infants, even when it is mild-to-moderate. Chronic hypertension is a risk factor for superimposed preeclampsia and results in higher rates of adverse outcome. Preeclampsia is a multisystemic disease that is thought to be initiated by abnormalities in placental perfusion and endothelial dysfunction, ultimately resulting in multiorgan failure. Preeclampsia is more common in women of minority ethnicity who are socioeconomically disadvantaged. Pharmacologic therapy for hypertensive disorders in pregnancy is limited by concerns regarding the safety of both mother and fetus. Although treatment of severe hypertension is not debated, there is no consensus on the rationale for pharmacologic therapy of mild-to-moderate hypertension in pregnancy.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Roberts J, Pearson G, Cutler J, Lindheimer M: Summary of the NHLBI Working Group on Research on Hypertension during Pregnancy. Hypertension 2003, 41:437–445. This document describes hypertension in pregnancy as a major cause of materal and fetal mortality and morbidity. It provides an overview of epidemiology, pathology, pathophysiology, risk factors, and linkage between oxidative stress and preeclampsia.PubMedCrossRefGoogle Scholar
  2. 2.
    Gifford RW, August PA, Cunningham G, et al.: Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000, 183:S1-S22. A very good article detailing the classification of pregnancy-induced hypertension.CrossRefGoogle Scholar
  3. 3.
    Montan S: Drugs used in hypertensive diseases in pregnancy. Current Opin Obstet Gynecol 2004, 16:111–115. An excellent review of antihypertensive drug therapy during pregnancy.CrossRefGoogle Scholar
  4. 4.
    Sibai B: Chronic hypertension in pregnancy. Obstet Gynecol 2002, 100:369–377. This is an expert’s view on chronic hypertension in pregnancy, which is defined as elevated blood pressure diagnosed before pregnancy. Sibai explains how low-risk and high-risk chronic hypertension should be managed and postpartum management of chronic hypertension.PubMedCrossRefGoogle Scholar
  5. 5.
    Burt VL, Whetton P, Rochella EJ, et al.: Prevalence of hypertension in the US adult population: results from the third national health and nutrition examination survey, 1988–1991. Hypertension 1995, 25:305–313.PubMedGoogle Scholar
  6. 6.
    Sibai BM, Villar MA, Mabie BC: Acute renal failure in hypertensive disorders of pregnancy: pregnancy outcome and remote prognosis in thirty-one consecutive cases. AmJ Obstet Gynecol 1990, 162:777–783.Google Scholar
  7. 7.
    Sibai BM, Lindheimer M, Hauth J, et al.: Risk factors for preeclampsia, abruption placentae, and adverse neonatal outcomes among women with chronic hypertension. N Engl J Med 1998, 339:667–671.PubMedCrossRefGoogle Scholar
  8. 8.
    Ferrer RL, Sibai BM, Murlow CD, et al.: Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol 2000, 96:849–860.PubMedCrossRefGoogle Scholar
  9. 9.
    August P, Helseth G, Cook F, et al.: A prediction model for superimposed preeclampsia in women with chronic hypertension during pregnancy. Am J Obstet Gynecol 2004, 191:1666–1672.PubMedCrossRefGoogle Scholar
  10. 10.
    Chelsey LC: Hypertensive Disorders of Pregnancy. New York, NY: Appleton-Century-Crofts: 1978.Google Scholar
  11. 11.
    Sibai B: Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003, 102:181–192. This review article describes definition and classification as well as the diagnosis, antepartum, intrapartum, and postpartum management of hypertension complicating pregnancy.PubMedCrossRefGoogle Scholar
  12. 12.
    Kaplan NM: Hypertension with pregnancy and the pill. In Kaplan’s Clinical Hypertension. Edited by Kaplan NM. Philadelphia: Lippincott Williams & Wilkins; 1994:343–365.Google Scholar
  13. 13.
    Dekker G, Sibai B: Pathogenesis and etiology of preeclampsia. Am J Obstet Gynecol 1998, 179:1359.PubMedCrossRefGoogle Scholar
  14. 14.
    Levine RJ, Maynard SE, Qian C, et al.: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672–683. This is a study that showed that increased levels of sFlt-1, an antiangiogenic protein, and reduced levels of PIGF predict the development of preeclampsia.PubMedCrossRefGoogle Scholar
  15. 15.
    Roberts JM: Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998, 16:5–15.PubMedGoogle Scholar
  16. 16.
    Gonzalez-Quintero VH, Smakursky LP, Jiminez JJ, et al.: Elevated plasma endothelial microparticles: preeclampsia versus gestational hypertension. Am J Obstet Gynecol 2004, 191:1418–1424.PubMedCrossRefGoogle Scholar
  17. 17.
    Roberts JM, Hubel CA: Is oxidative stress the link in the two-stage model of pre-eclampsia? (letter) Lancet 1999, 354:788–789.PubMedGoogle Scholar
  18. 18.
    Roberts JM, Hubel CA: Oxidative stress in preeclampsia. Am J Obstet Gynecol 2004, 190:1177–1178.PubMedCrossRefGoogle Scholar
  19. 19.
    Sibai B, El-Nazer A, Gonzalez-Ruiz A: Severe preeclampsiaeclampsia in young primigravid women: subsequent outcome and remote prognosis. Am J Obstet Gynecol 1986, 155:1011–1016.PubMedGoogle Scholar
  20. 20.
    Hubel C, Roberts J: Lipid metabolism and oxidative stress. In Chesley’s Hypertensive Disorders in Pregnancy. Edited by Lindheimer M, Roberts J, Cunningham F. Stamford, CT: Appleton & Lange; 1999:453–486.Google Scholar
  21. 21.
    Redman CW, Sacks GP, Sargent IL: Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999, 180:499–506.PubMedCrossRefGoogle Scholar
  22. 22.
    Dekker G, Sibai B: Primary, secondary, and tertiary prevention of preeclampsia. Lancet 2001, 357:209–215.PubMedCrossRefGoogle Scholar
  23. 23.
    Kinzler W, Smulian J, Ananth C, et al.: Noninvasive ultrasound measurement of maternal vascular reactivity during pregnancy: a longitudinal study. Obstet Gynecol 2004, 104:362–366.PubMedGoogle Scholar
  24. 24.
    Levine R, Thadhani R, Qian C, et al.: Urinary placental growth factor and risk of preeclampsia. JAMA 2005, 293:77–85.PubMedCrossRefGoogle Scholar
  25. 25.
    Cockburn J, Moar VA, Ounsted M, Redman CW: Final report of the study on hypertension during pregnancy; the effects of specific treatment on the growth and development of the children. Lancet 1982, 1:647–649.PubMedCrossRefGoogle Scholar
  26. 26.
    Barrilleaux P, Marin J: Hypertension therapy during pregnancy. Clinical Obstet Gynecol 2002, 45:22–24.CrossRefGoogle Scholar
  27. 27.
    Magee LA, Duley L: Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2003, 3:CD002863.PubMedGoogle Scholar
  28. 28.
    Rubin PC, Butters L, Clark DM, et al.: Placebo controlled trial of atenolol in pregnancy-associated hypertension. Lancet 1983, I:431–434.Google Scholar
  29. 29.
    Easterling TR, Carr B, Brateng DB, et al.: Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery and fetal growth. Obstet Gynecol 2001, 98:427–433.PubMedCrossRefGoogle Scholar
  30. 30.
    Reynolds B, Butters L, Evans J, et al.: First year of life after use of atenolol in pregnancy. Arch Dis Child 1984, 59:1061–1063.PubMedGoogle Scholar
  31. 31.
    El-Qarmalawi AM, Morsy AH, al-Fadly A, et al.: Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynaecol Obstet 1995, 49:125–130.PubMedCrossRefGoogle Scholar
  32. 32.
    MacPherson M, Pipkin FB, Rutter N, et al.: The effect of maternal labetalol on the newborn infant. Br J Obstet Gynaecol 1986, 93:539–542.PubMedGoogle Scholar
  33. 33.
    Constantine G, Beevers D, Reynolds A, et al.: Nifedipine as a second line antihypertensive drug in pregnancy. Br J Obstet Gynecol 1987, 94:1136–1142.Google Scholar
  34. 34.
    Bortolus R, Ricci E, Chatenoud L, et al.: Nifedipine administered in pregnancy. Effect on development of children at 18 months. BJOG 2000, 107:792–794.PubMedCrossRefGoogle Scholar
  35. 35.
    Fenakel K, Fenakel G, Appelman Z, et al.: Nifedipine in the treatment of severe pre-eclampsia. Obstet Gynecol 1991, 77:331–337.PubMedGoogle Scholar
  36. 36.
    Stempel J, O’Grady J, Morton M, et al.: Use of sodium nitroprusside in complications of gestational hypertension. Obstet Gynecol 1982, 60:533–538.PubMedGoogle Scholar
  37. 37.
    Collins R, Yusuf S, Peto R: Overview of randomized trials of diuretics in pregnancy. Br Med J 1985, 290:17–23.Google Scholar
  38. 38.
    Arias F, Zamora J: Antihypertensive treatment and pregnancy outcome in patients with mild chronic hypertension. Obstet Gynecol 1979, 53:489–494.PubMedGoogle Scholar
  39. 39.
    Chung N, Beevers A, Gareth D, et al.: Management of hypertension in pregnancy. Am J Cardiovasc Drugs 2001, 1:253–262.PubMedCrossRefGoogle Scholar
  40. 40.
    Sedman A, Kershaw DB, Buncjman TE: Recognition and management of angiotensin converting enzyme inhibitor fetopathy. Pediatr Nephrol 1995, 9:382–385.PubMedCrossRefGoogle Scholar
  41. 41.
    Burrows RF, Burrows EA: Assessing the teratogenic potential of angiotensin converting enzyme inhibitors in pregnancy. Aust N Z J Obstet Gynecol 1998, 38:306–311.Google Scholar
  42. 42.
    Lip GY, Churchill D, Beevers M, et al.: Angiotensin-convertingenzyme inhibitors in early pregnancy. Lancet 1997, 350:1446–1447.PubMedCrossRefGoogle Scholar
  43. 43.
    Chung N, Lip GY, Beevers M, et al.: Angiotensin II converting enzyme inhibitors in pregnancy. Lancet 2001, 357:1620.PubMedCrossRefGoogle Scholar
  44. 44.
    Churchill D, Beevers DG: Hypertension in Pregnancy. London: BMJ Books; 1999.Google Scholar
  45. 45.
    Duley L, Henderson-Smart D: Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev 2003, 4:CD000128.PubMedGoogle Scholar
  46. 46.
    Griffis KR, Martin JN, Palmer SM, et al.: Utilization of hydralazine or methyldopa for the management of early puerperal hypertension. Am J Perinatol 1989, 6:437–441.PubMedCrossRefGoogle Scholar
  47. 47.
    Sibai BM, Mercer B, Saringlu C, et al.: Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991, 165:140.Google Scholar
  48. 48.
    Atallah AN, Hofmeyr GJ, Duley L: Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2002, 1:CD001059.PubMedGoogle Scholar
  49. 49.
    Duley L, Henderson-Smart D, Knight M, et al.: Antiplatelet drugs for prevention of preeclampsia and its consequences. BMJ 2001, 322:329–333.PubMedCrossRefGoogle Scholar
  50. 50.
    Vainio M, Riutta A, Koivisto AM, et al.: Prostacyclin, thromboxane A and the effect of low dose aspirin in pregnancies at high risk of hypertensive disorders. Act Obstet Gynecol Scand 2004, 83:1119–1123.CrossRefGoogle Scholar
  51. 51.
    Sibai BM, Taslimi MM, El-Nazer A, et al.: Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia. Am J Obstet Gynecol 1986, 155:501–509.PubMedGoogle Scholar
  52. 52.
    Sibai BM: Diagnosis controversies and management of the syndrome of hemolysis, elevated liver enzymes and low platelet count. Obstet Gynecol 2004, 103:981–991.PubMedGoogle Scholar
  53. 53.
    Audibert F, Friedman SA, Frangieh AY, et al.: Clinical utility of strict diagnostic criteria for the HELLP syndrome. Am J Obstet Gynecol 1996, 175:460–464.PubMedCrossRefGoogle Scholar
  54. 54.
    Abramovici D, Friedman SA, Mercer BM, et al.: Neonatal outcome in severe preeclampsia at 24 to 36 weeks gestation: Does HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Am J Obstet Gynecol 1999, 180:221–225.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Maryann Mugo
    • 1
  • Gurushankar Govindarajan
    • 1
  • L. Romayne Kurukulasuriya
    • 1
  • James R. Sowers
    • 1
  • Samy I. McFarlane
    • 1
  1. 1.University of Missouri-Columbia and the Harry S. Truman Memorial Veterans Administration HospitalColumbiaUSA

Personalised recommendations